dorsaVi signs new contracts in the US healthcare market

dorsaVi (ASX:$DVL) has signed two new contracts with leading US institutions for a total value of approximately AU$168,500 over a 2-year period. The agreements with Norton Healthcare and Georgia Southern University will support research on dorsaVi's product line, enhancing its top-tier client base and diversifying the Company's revenue stream.

Executive Commentary

We are excited to be working with two highly esteemed institutions, Georgia Southern University and Norton Healthcare. It is a privilege for our company to be guided by the expertise of both Dr. Steven Glassman and Associate Professor Worst, who are pre-eminent leaders in their respective fields. These contracts are a great endorsement of our platform capability, and further validation of our growing presence in the US healthcare market. Our continued alignment with top-tier institutions reflects our dedication to generating shareholder value as we continue to partner with leading companies across the healthcare market.

Summary of dorsaVi's New Contracts

dorsaVi (ASX:DVL) has secured two new contracts with Norton Healthcare and Georgia Southern University, marking a significant step forward in the US healthcare space. The agreements, valued at approximately AU$168,500 over a 2-year period, will support research on dorsaVi's product line, enhance its top-tier client base, and diversify the Company's revenue stream. These multi-year deals signify a material advancement in the US healthcare market, building on the momentum of the University of Rochester contract earlier in the year. The company expects to derive new insights into patterns of human movement from both projects, potentially enhancing outcomes for patients dealing with spinal conditions and stress fractures related to running. The clinical data gained from the studies will pave the way for further refinement and advancement of dorsaVi's sensor technology, aligned with the company's commitment to constant innovation.